Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer

Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer

Background The lung immune prognostic index (LIPI) is a marker that combines the derived neutrophil‐to‐lymphocyte ratio (dNLR) and serum lactate dehydrogenase (LDH) level and is a recently reported prognostic factor of immune checkpoint inhibitor therapy for non‐small cell lung cancer (NSCLC). Howev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thoracic cancer 2020-06, Vol.11 (6), p.1578-1586
Hauptverfasser: Sonehara, Kei, Tateishi, Kazunari, Komatsu, Masamichi, Yamamoto, Hiroshi, Hanaoka, Masayuki
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Age
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Cancer therapies
Chemotherapy
Combined Modality Therapy
Dehydrogenases
Derived neutrophil‐to‐lymphocyte ratio
Female
Follow-Up Studies
Humans
Lung cancer
lung immune prognostic index
Lung Neoplasms - immunology
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Lymphatic system
Lymphocytes
Lymphocytes - immunology
Lymphocytes - pathology
Male
Medical prognosis
Middle Aged
Neutrophils
Neutrophils - immunology
Neutrophils - pathology
Original
Patients
Pneumonia
Prognosis
prognostic factor
Radiation therapy
Retrospective Studies
serum lactate dehydrogenase
small cell lung cancer
Small Cell Lung Carcinoma - immunology
Small Cell Lung Carcinoma - pathology
Small Cell Lung Carcinoma - therapy
Statistical analysis
Survival Rate
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The lung immune prognostic index (LIPI) is a marker that combines the derived neutrophil‐to‐lymphocyte ratio (dNLR) and serum lactate dehydrogenase (LDH) level and is a recently reported prognostic factor of immune checkpoint inhibitor therapy for non‐small cell lung cancer (NSCLC). However, there are no reports regarding the prognostic value of LIPI in small cell lung cancer (SCLC). Methods We retrospectively enrolled 171 patients diagnosed with SCLC and treated at Shinshu University School of Medicine between January 2003 and November 2019. Progression‐free survival (PFS) and overall survival (OS) were compared according to LIPI, and we investigated whether LIPI could be a prognostic factor in SCLC using the Kaplan‐Meier method and univariate and multivariate Cox models. Results The median OS of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (21.0 vs. 11.6 months, P 
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.13432